Exelixis (NASDAQ:EXEL) Coverage Initiated by Analysts at Brookline ...

Dec 23, 2024 · Several other analysts have also recently weighed in on the company. Morgan Stanley lifted their price objective on Exelixis from $26.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, October 11th. Piper Sandler upped their …

$26.00
OFF

Exelixis (NASDAQ:EXEL) Coverage Initiated By Analysts At Brookline ...

2 weeks from now

marketbeat.com

$33.48
OFF

Exelixis (NASDAQ:EXEL) Coverage Initiated By Analysts At Brookline ...

2 weeks from now

Dec 24, 2024 · Exelixis stock opened at $33.48 on Monday. Exelixis has a fifty-two week low of $19.20 and a fifty-two week high of $36.97. The stock has a market cap of $9.56 billion, a P/E …

defenseworld.net

$40
OFF

Exelixis Initiated At Buy With $40 Price Target Amid Promising …

2 weeks from now

Dec 27, 2024 · Brookline Capital Markets analysts initiated coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and a $40 price target, highlighting the biotechnology company’s potential for …

cweb.com

$40
OFF

Exelixis Initiated At Buy With $40 Price Target Am...

2 weeks from now

May 14, 2024 · Brookline Capital Markets analysts initiated coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and a $40 price target, highlighting the biotechnology …

financialmodelingprep.com

48%
OFF

Brookline Capital Initiates Coverage Of Exelixis (EXEL) With Buy

2 weeks from now

Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy recommendation. Analyst Price Forecast Suggests 0.48% …

msn.com

$33.82
OFF

Exelixis (NASDAQ:EXEL) Now Covered By Brookline Capital …

2 weeks from now

Dec 25, 2024 · Exelixis stock opened at $33.82 on Monday. The firm has a market capitalization of $9.66 billion, a price-to-earnings ratio of 21.68, a PEG ratio of 0.89 and a beta of 0.52.

etfdailynews.com

$42.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $42.00 - MarketBeat

2 weeks from now

15 hours ago · Brookline Capital Management assumed coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a "buy" rating for the company. TD …

marketbeat.com

$40.00
OFF

Exelixis Stock Price Today | NASDAQ: EXEL Live - Investing.com

2 weeks from now

Jan 6, 2017 · An analyst from Brookline Capital Markets initiated coverage of Exelixis (NASDAQ: EXEL) at 'buy' with a price target of $40.00. ... An analyst from Brookline Capital Markets …

investing.com

$40
OFF

Oppenheimer Bullish On Exelixis Stock As Cabo Sales And R&D …

2 weeks from now

7 hours ago · Brookline Capital Markets initiated coverage on Exelixis with a Buy rating and a price target of $40, foreseeing significant growth in sales of existing products and successful …

investing.com

$36.98
OFF

Exelixis Stock Hits 52-week High At $36.98 Amid Robust Growth

2 weeks from now

1 day ago · Exelixis Inc . (NASDAQ: EXEL) stock soared to a 52-week high of $36.98, reflecting a remarkable year of growth for the biotechnology firm. Investors have shown increasing …

investing.com

$40
OFF

Truist Raises Exelixis Stock Target, Buy Rating Held On Sales Potential

2 weeks from now

1 day ago · Meanwhile, Brookline Capital Markets initiated coverage on Exelixis with a Buy rating and a price target of $40, projecting significant growth in sales of existing products and …

investing.com

$36.98
OFF

Exelixis Stock Hits 52-week High At $36.98 Amid Robust Growth

2 weeks from now

1 day ago · Exelixis Inc . (NASDAQ: EXEL) stock soared to a 52-week high of $36.98, reflecting a remarkable year of growth for the biotechnology firm. Investors have shown increasing …

investing.com

$26.00
OFF

Burney Co. Acquires New Position In Exelixis, Inc. (NASDAQ:EXEL)

2 weeks from now

1 day ago · Stifel Nicolaus raised their price target on Exelixis from $26.00 to $30.00 and gave the company a "hold" rating in a research report on Wednesday, October 16th. Finally, UBS …

marketbeat.com

$36.98
OFF

Exelixis Stock Hits 52-week High At $36.98 Amid Robust Growth

2 weeks from now

1 day ago · Exelixis Inc . (NASDAQ: EXEL) stock soared to a 52-week high of $36.98, reflecting a remarkable year of growth for the biotechnology firm.Investors have shown increasing …

investing.com

$1
OFF

Exelixis Reports Strong $1.8B Revenue For 2024, Projects Growth In …

2 weeks from now

3 days ago · Exelixis (NASDAQ: EXEL) has announced preliminary fiscal year 2024 results and 2025 guidance. The company achieved approximately $1.805 billion in preliminary U.S. net …

stocktitan.net

FAQs about Exelixis (NASDAQ:EXEL) Coverage Initiated by Analysts at Brookline ... Coupon?

Should you buy Exelixis (Exel) in 2024?

Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy recommendation. Analyst Price Forecast Suggests 0.48% Downside As of December 3, 2024, the average one-year price target for Exelixis is $33.32/share. The forecasts range from a low of $23.23 to a high of $40.95. ...

Does Bank of America buy Exelixis?

Bank of America cut Exelixis from a “buy” rating to a “neutral” rating and boosted their target price for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. UBS Group began coverage on Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price for the company. ...

Is Exelixis a good stock to buy?

Guggenheim lifted their price target on shares of Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. ...

What is the average price target for Exelixis?

As of December 3, 2024, the average one-year price target for Exelixis is $33.32/share. The forecasts range from a low of $23.23 to a high of $40.95. The average price target represents a decrease of 0.48% from its latest reported closing price of $33.48 / share. See our leaderboard of companies with the largest price target upside. ...

How many funds own Exelixis?

There are 1,008 funds or institutions reporting positions in Exelixis. This is an increase of 48 owner (s) or 5.00% in the last quarter. Average portfolio weight of all funds dedicated to EXEL is 0.33%, an increase of 2.57%. Total shares owned by institutions increased in the last three months by 8.55% to 298,918K shares. ...

Who bought Exelixis?

V Square Quantitative Management LLC bought a new stake in Exelixis in the 3rd quarter valued at $30,000. Brooklyn Investment Group acquired a new position in shares of Exelixis in the third quarter valued at $42,000. Capital Performance Advisors LLP bought a new position in shares of Exelixis in the third quarter valued at about $61,000. ...